ArticleAdvanced healthcare materials2026
A Systematic Study of GelMA-Carbopol Bioinks for High-Fidelity Extrusion 3D Bioprinting at Physiological Temperatures.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Extrusion 3D bioprinting allows depositing cells within hydrogels in well-defined spatial patterns, facilitating the creation of tissue biomimetics. Gelatin methacrylate (GelMA) hydrogels are biocompatible, biodegradable, and promote cell adhesion, making them a common choice to formulate bioinks. However, the low viscosity of GelMA-based inks makes it challenging to print at physiological temperatures. Typically, this is overcome with high concentrations (≥ 10%) of GelMA and rheological modifiers (≥ 1%), and using low temperatures, which negatively impact the printing process and cell function. This work develops high performance GelMA bioinks using Carbopol (CBP) as a rheology modifier. Inks containing low GelMA and CBP concentrations exhibit excellent printability at physiological temperatures. Complex constructs, including hollow structures with overhangs, were 3D printed with high shape fidelity. The inks show excellent cytocompatibility toward various cells, including primary human lung fibroblasts (HLF). HLF embedded in bioprinted structures exhibited outstanding viability and proliferated over 14 days of continuous culture. As an application, GelMA-CBP inks were used to fabricate a stretchable lung tissue model incorporating HLFs, which was used to study fibroblast-to-myofibroblast transition. This work resolves limitations of traditional GelMA 3D bioprinting inks and lays the foundation for their use in advanced tissue biomimetics and regenerative medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.